

Master Service Agreement signed with large US reference laboratory

Q-linea AB (publ) (OMX: QLINEA) today announces the signing of a multi-year agreement between Q-linea, Inc. and a large national reference laboratory.

ASTar instrumentation will be placed at pilot sites strategically located throughout the country with deployment expected to begin in Q2 2025.

Jim Kathrein, VP of US Commercial Operations, stated, “We are eager to move forward with the initiation of this partnership and anticipate an expansion as results are realized.”

Previous communication, January 24, 2025: https://qlinea.com/mfn_news/continued-commercial-progress-with-us-reference-laboratory/?ln=en

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-07 23:47 CET.

Attachments

[Master Service Agreement signed with large US reference laboratory](#)